Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EN3285 for severe oral mucositis in head and neck cancer
NCT00574860Phase 3Terminated
- Sponsor
- Endo International plc
- Start
- Dec 2007
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in oral mucositis (OM) comparing EN3285 (NAC ProGelz), Placebo and Standard of Care (3 arms). Primary endpoint: NCI v3 to measure severity of OM. Started Dec 2007; status: terminated.
02
Drugs
EN3285
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT00574860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00574860.